Statins — patient guide

This page covers all the medicines in the statin family. If your medicine’s name ends in -statin, this is your page.

---

Start here — the honest conversation

You’re reading this because you’ve been told to take a statin, or you’ve been on one, and you’re not sure about it. Maybe a family member had a bad experience. Maybe you’ve read content online that says statins are dangerous and useless. Maybe your muscles ache and you suspect the tablet. Maybe you just don’t like the idea of being on a lifelong medicine for a number on a piece of paper.

All of that is reasonable. None of it is silly. Statins are one of the most-prescribed medicines in the world and also one of the most-argued-about, and both of those things are true for real reasons.

Here is the shape of the conversation worth having.

The trial evidence for statins, across more than thirty years and hundreds of thousands of patients, is genuine. The Cholesterol Treatment Trialists meta-analysis pooled 27 randomised trials and found roughly a 22% reduction in major vascular events for every 1 mmol/L of LDL cholesterol lowered. That benefit is largest in secondary prevention — people who have already had a heart attack or stroke — and in familial hypercholesterolaemia. It is smaller and more contested in low-risk primary prevention.

Side effects are also real. Muscle aches happen. A small new-onset diabetes signal is real. A rare but serious rhabdomyolysis risk exists, mostly when drug interactions push statin levels up.

Hold both of these things in your head at the same time, because they’re both true. This page walks you through which group you’re in, what to expect, and what to ask.

---

Find your medicine

Generic name	Common brand names	Strengths	How often
Atorvastatin	Lipitor, Atorvachol, Lorstat, generics	10 / 20 / 40 / 80 mg	Once daily
Rosuvastatin	Crestor, generics	5 / 10 / 20 / 40 mg	Once daily
Simvastatin	Zocor, Lipex, generics	5 / 10 / 20 / 40 / 80 mg	Once at night
Pravastatin	Pravachol, generics	10 / 20 / 40 / 80 mg	Once daily (often at night)
Fluvastatin	Lescol XL	80 mg (extended-release)	Once daily
Pitavastatin	Livazo	1 / 2 / 4 mg	Once daily

Why simvastatin is dosed at night. Cholesterol synthesis is greater overnight and simvastatin’s half-life is short, so the dose is timed to match. Atorvastatin and rosuvastatin have long half-lives — they work whatever time of day you take them. Consistency matters more than the specific time.

80 mg simvastatin note. The SEARCH trial showed an increased rhabdomyolysis signal at 80 mg compared with 20 mg. AU practice is to avoid starting at 80 mg and to continue it only in patients already tolerating it long term without muscle symptoms.

Closely related — ezetimibe (Ezetrol, also in combination tablets like Atozet and Vytorin). Different mechanism — it blocks cholesterol absorption in the gut instead of synthesis in the liver. Often added when a statin alone doesn’t reach the LDL target, or when statin dose can’t go higher.

Closely related — PCSK9 inhibitors (alirocumab, evolocumab). Injectable; specialist territory; very effective LDL lowering for patients who can’t tolerate statins or who have familial hypercholesterolaemia with persistently high LDL on maximum statin.

---

Hydrophilic vs lipophilic — in plain English

Statins come in two flavours.

Hydrophilic — water-loving — statins: rosuvastatin, pravastatin, fluvastatin. They stay mostly outside cells, are processed by enzymes that don’t interact much with common medicines (and don’t interact with grapefruit), and have less brain penetration.

Lipophilic — fat-loving — statins: atorvastatin, simvastatin, lovastatin. They cross cell membranes more readily, are metabolised by an enzyme called CYP3A4 (which also handles many common medicines and grapefruit), and have more brain penetration.

This isn’t about which is better. It’s about which suits your situation. If you’re on a medicine that interacts with CYP3A4 — common ones include the antibiotic clarithromycin, the antifungal itraconazole, the heart-rhythm drug amiodarone, and the calcium channel blockers diltiazem and verapamil — a hydrophilic statin avoids the interaction headache. If you’ve had muscle or cognitive symptoms on a lipophilic statin, a switch to a hydrophilic one is often the next step.

---

Intensity tiers — where does your dose sit?

These tiers come from US cardiology guidelines. We use them in AU too. They tell you roughly how much your LDL will drop on your dose.

High intensity (LDL lowered by ~50% or more):

• Atorvastatin 40-80 mg
• Rosuvastatin 20-40 mg

Moderate intensity (LDL lowered by ~30-49%):

• Atorvastatin 10-20 mg
• Rosuvastatin 5-10 mg
• Simvastatin 20-40 mg
• Pravastatin 40-80 mg
• Fluvastatin XL 80 mg
• Pitavastatin 2-4 mg

Low intensity (LDL lowered by under 30%):

• Simvastatin 10 mg
• Pravastatin 10-20 mg
• Fluvastatin 20-40 mg
• Pitavastatin 1 mg

Your GP picks the intensity based on your indication. Secondary prevention and familial hypercholesterolaemia usually call for high intensity. Primary prevention with moderate absolute risk often sits at moderate intensity. People who have had muscle symptoms or interaction issues may be at a lower intensity on a different statin.

---

What it actually does

Statins block an enzyme called HMG-CoA reductase, which is the rate-limiting step in your liver’s cholesterol synthesis pathway. Less cholesterol made → the liver pulls more LDL out of the blood to make up the difference → blood LDL drops.

The cardiovascular benefit is bigger than the LDL drop alone would predict. Statins also stabilise atherosclerotic plaque (less prone to rupture), have a mild anti-inflammatory effect, and improve endothelial function. This is why outcome trials show event reductions even in patients whose starting LDL is already in the average range — the JUPITER trial is the canonical example.

---

Who actually benefits most

This is the part the internet usually skips.

Strongest benefit — almost no one argues:

• You’ve had a heart attack, stroke, or revascularisation (secondary prevention). The 4S trial and the Heart Protection Study are the foundational evidence.
• You have familial hypercholesterolaemia (genetic high cholesterol from birth — usually flagged by very high LDL or a strong family history of early heart attacks).
• You have type 2 diabetes plus other CV risk factors.

Good benefit — the case is solid:

• You meet the 2023 Heart Foundation absolute CV risk guideline threshold for primary prevention. This uses age, sex, smoking, BP, cholesterol, diabetes status, and other factors to estimate your 5-year risk of a cardiovascular event. The conversation about a statin happens when that risk is high or, in some cases, intermediate with extra qualifiers.

Weaker case — the conversation is real:

• You’re a low-absolute-risk primary-prevention patient and the statin is being suggested mainly because your LDL number is high in isolation.
• You’re elderly with significant other illness and a limited life expectancy, where the time-to-benefit of a statin (years) outweighs the likely benefit window.

If you’re in the weaker-case group, the conversation worth having is “what is my actual absolute risk, what’s my LDL doing, what does lifestyle change look like, and is this medicine the right next step right now.” That conversation belongs in the consult, not online.

---

Tap any section below to expand the detail.

Side effects in detail

Common (usually mild)

• Muscle symptoms (myalgia). Aches, tenderness, or weakness — most often proximal (thighs, shoulders, hips). Observational rate is around 10-15%; randomised-trial rate is lower (1-5%). The SAMSON trial showed that in patients who had previously stopped statins for side effects, symptom intensity on placebo was nearly identical to symptom intensity on statin — and both were far higher than on no tablet at all. Both things are true: symptoms are real, AND a meaningful portion is the nocebo effect (the body producing the symptom it expects). The clinical move when symptoms appear is to check creatine kinase (a muscle enzyme) and vitamin D, then trial pause-and-rechallenge, dose reduction, or switch to a different statin — usually a hydrophilic one.

• Mild rise in liver enzymes (ALT/AST). Usually transient, asymptomatic, and settles on continuation or dose reduction. Significant elevation (greater than 3x the upper limit of normal, sustained) is a different conversation.

• Gastrointestinal upset, headache, fatigue in the first weeks — usually settles.

Uncommon

• New-onset diabetes. About 1 extra case per 1,000 patient-years at moderate intensity; about 3 extra per 1,000 patient-years at high intensity. Risk concentrated in patients with metabolic syndrome features (prediabetes, central obesity, raised triglycerides, low HDL). The Sattar et al. meta-analysis is the source. Net benefit on cardiovascular events substantially outweighs the diabetes risk in patients with appropriate indications.

• Cognitive complaints — fogginess, memory niggles. Reported anecdotally; not consistently demonstrated in randomised trials. If they occur, a trial off the statin (or switch to a hydrophilic one) is reasonable.

Rare but serious — call 000 or go to ED

• Rhabdomyolysis. Severe muscle pain plus dark / tea-coloured urine plus marked CK elevation (often more than 10x normal). Rate under 1 in 10,000 patient-years for moderate-intensity therapy. Amplified by CYP3A4-interacting drugs (macrolides, azoles, amiodarone, certain calcium channel blockers, grapefruit at high intake). Stop the statin and present urgently.

• Persistent elevation of liver enzymes greater than 3x normal — usually warrants pause and investigation rather than immediate ED, but message us.

Haemorrhagic stroke signal (recurrent-stroke setting only)

• The SPARCL trial (NEJM 2006) tested high-intensity atorvastatin 80 mg in patients with a prior stroke or TIA. The overall result was favourable for ischaemic stroke and major vascular events, but a small absolute increase in haemorrhagic stroke (about 2.3% vs 1.4% over five years) was observed. For most patients the net cardiovascular benefit still outweighs the haemorrhagic-stroke signal, but if you’ve had a prior haemorrhagic stroke or have known cerebral microbleeds, the calculus is different. This is a conversation with your neurologist and us together.

Drug interactions to know about

This is where the statin family rewards care — the difference between hydrophilic and lipophilic statins actually matters here.

For atorvastatin, simvastatin, and lovastatin (CYP3A4-metabolised):

• Macrolide antibiotics — clarithromycin and erythromycin substantially raise statin levels. The usual move is to pause the statin during the antibiotic course. Azithromycin is much lower risk.
• Azole antifungals — itraconazole, ketoconazole, posaconazole. Same CYP3A4 issue. Pause the statin during systemic azole therapy or switch class baseline.
• Amiodarone, diltiazem, verapamil. Raise simvastatin and (to a lesser extent) atorvastatin exposure. Dose limits apply — simvastatin caps at 20 mg with amiodarone or verapamil, and at 40 mg with diltiazem.
• Grapefruit juice. High daily intake (more than ~1 L) meaningfully raises blood levels of CYP3A4 statins. Occasional small servings are clinically minor.
• HIV protease inhibitors and hepatitis C direct-acting antivirals. Complex; specialist input needed.

For all statins:

• Fibrates (gemfibrozil, fenofibrate). Combination raises myopathy and rhabdomyolysis risk — particularly gemfibrozil. Gemfibrozil + statin is generally avoided. Fenofibrate is preferred if combination is needed (eg. mixed dyslipidaemia with very high triglycerides) — specialist territory.
• Ciclosporin, tacrolimus. Raise levels of most statins — significant dose adjustments and specialist input required.
• Colchicine. Additive myopathy signal, especially in renal impairment.
• Warfarin. Statins can modestly raise INR — particularly fluvastatin and rosuvastatin. Check INR after starting or changing the statin.
• Red yeast rice supplements. Contain monacolin K (= lovastatin). Do not combine — additive statin effect.

For rosuvastatin, pravastatin, fluvastatin, pitavastatin: the CYP3A4 interactions above mostly don’t apply. This is the main reason to pick one of these statins if you’re on a long-term interacting medicine.

Pregnancy and breastfeeding

The AU stance is to avoid statins in pregnancy and breastfeeding.

The theoretical concern is that cholesterol is required for normal fetal development — statins are a class effect. Post-marketing data over the last decade has been more reassuring than the original 1980s concern suggested, and the ACC/AHA position internationally has softened in selected very-high-risk patients (eg. familial hypercholesterolaemia after a heart attack). That is specialist territory; on the public surface, the AU position is avoid.

Planning a pregnancy: tell us before trying. We stop the statin and manage lipids with lifestyle plus non-statin agents as appropriate. The risk window opens at conception.

Already on a statin and just found out you’re pregnant: stop the tablet and contact us as soon as you can. Don’t panic — the actual harm signal in human data is small — but don’t take the next dose until we’ve talked.

Breastfeeding: also avoid. Statins are excreted in breast milk. The decision when to restart after delivery depends on whether you’re breastfeeding and on your CV risk.

Monitoring — what blood tests and when

• Before starting: baseline LFTs (ALT/AST), lipid panel, CK if there are baseline muscle symptoms, fasting glucose or HbA1c, kidney function.
• 12 weeks after starting (or after a dose change): repeat LFTs and lipid panel to check the LDL response.
• 6-12 months in: repeat LFTs, lipid panel, HbA1c. Then annually if everything is stable.
• CK — checked at baseline if there are baseline muscle issues, and any time muscle symptoms appear on the statin. We don’t routinely repeat it in asymptomatic patients.
• HbA1c — repeated at routine review because of the small new-onset diabetes signal.

Mild transient ALT rises in the first 12 weeks are common and usually settle on continuation. Persistent rises greater than 3x normal warrant pause and investigation.

If you’re on a combination tablet

Several statins are pre-combined with other CV medicines:

• Caduet = amlodipine (a calcium channel blocker for BP) + atorvastatin. Useful if you have both hypertension and elevated CV risk.
• Atozet = atorvastatin + ezetimibe. Used when atorvastatin alone doesn’t reach the LDL target, or when statin dose can’t go higher.
• Vytorin / Inegy / Goltor = simvastatin + ezetimibe. AU branding has shifted over time — confirm which brand you have with your pharmacist.

Everything on this page applies to the statin portion of your combination tablet. The other component has its own profile — ask us, or check the relevant page when it’s ready.

Cost

Most statins are on the PBS. From 1 January 2026, the PBS co-payment is:

• General patient: up to $25.00 per script
• Concession card holder: up to $7.70 per script

PBS authority requirements apply to some statins for primary prevention — the relevant threshold from the Heart Foundation absolute-risk guideline determines whether you qualify. Your GP works this out at the time of prescribing.

Generic versions cost the same as branded ones at PBS pricing and work the same. Confirm the price for your specific script with your pharmacist.

(MBS / PBS items verified 2026-05-24 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

---

The integrative view

Most patients I see want to do everything they reasonably can in addition to — and sometimes instead of — the medicine. This section is the longer version of that conversation.

Two principles. First: statins work, and the trial evidence is among the strongest in cardiovascular medicine. Lifestyle changes also work, often more than people realise, AND they work on outcomes the LDL number doesn’t fully capture. Combined, they work better than either alone. Second: medicines aren’t always permanent. For primary prevention, if you genuinely change your eating, movement, weight, alcohol, and smoking status, your absolute risk may drop enough that we can reduce the dose — sometimes come off it. We do that together, with monitoring, not on your own. For secondary prevention and familial hypercholesterolaemia, the statin usually stays regardless.

Strong evidence — these reliably reduce CV events

• Mediterranean-style eating pattern. The PREDIMED trial (NEJM 2018) showed roughly a 30% reduction in major CV events in people eating a Mediterranean pattern enriched with olive oil or nuts — and that benefit appeared even though LDL barely moved. The eating pattern does more than the cholesterol number suggests. Build meals around vegetables, fruit, legumes, fish, nuts, olive oil, whole grains; minimise ultra-processed food.
• Aerobic exercise. 150 minutes/week of brisk walking, cycling, swimming, or equivalent. Independent CV protection regardless of what it does to your lipid numbers.
• Resistance training. 2-3 sessions/week. Adds protection on top of aerobic.
• Smoking cessation. The single biggest CV lever available outside the medicine. If you smoke and you take a statin, the smoking is doing more damage than the statin is fixing.
• Alcohol moderation. Heavy drinking pushes triglycerides up and BP around; cutting back has a real CV signal.
• Weight management. Even modest sustained weight loss improves the lipid panel and the BP and the HbA1c together.
• DASH-style eating pattern. Lowers BP by 6-11 mmHg systolic — and BP is an independent CV driver alongside lipids.

Moderate evidence — likely helpful

• Soluble fibre (oats, psyllium, legumes, apples). Modest LDL reduction of roughly 5-10%. Cheap, low-risk, makes lipid numbers move. Worth doing.
• Plant stanols and sterols (added to certain margarines and yoghurts in AU). Modest LDL reduction of 5-10%.
• Omega-3 (EPA/DHA). The REDUCE-IT trial showed icosapent ethyl 4 g/day reduced CV events in patients with high triglycerides who were already on a statin. Icosapent ethyl is the prescription EPA-only product — not chemically equivalent to over-the-counter mixed-EPA/DHA fish oil — and AU PBS availability is limited. Over-the-counter fish oil 2-4 g/day still has modest triglyceride-lowering effect.
• Stress reduction practices — meditation, slow breathing (around 6 breaths/minute), yoga. Modest BP benefit; possible independent CV benefit through autonomic balance.

Limited or emerging evidence

• Berberine. Modest LDL reduction (5-10%). Of interest in patients who are genuinely statin-intolerant. Talk to your GP — interactions and quality control vary.
• Red yeast rice. Effectively a low-dose statin (see the section above and the FAQ). Not an alternative; it’s the same molecule.
• Bergamot extract. Some small studies show modest LDL reduction. Quality of evidence is thin.

Specific to being on a statin

• CoQ10 (ubiquinone). Statins reduce serum CoQ10 by roughly 30-40% — that part isn’t contested. Whether supplementation reduces statin-related muscle symptoms is unsettled — the Banach meta-analysis was equivocal and the Cochrane review concluded the evidence is inconclusive. My pragmatic position: in a patient with unexplained statin myalgia where the alternative is stopping a useful medicine, a trial of CoQ10 100-200 mg daily for 4-8 weeks is reasonable. Start at 100 mg with food. See how you respond inside two months. Adjust up or down. If it’s not moving, that tells you something useful — the symptoms may have a different driver. I don’t routinely recommend CoQ10 to asymptomatic patients on a statin.
• Vitamin D status. Low vitamin D is associated with worse statin-related muscle symptoms. If you develop muscle symptoms on a statin, check the 25-OH-D level. Supplement to a target of 75-100 nmol/L. Same logic applies to magnesium — adequate intake from food (leafy greens, nuts, seeds, legumes) supports muscle function generally.
• Grapefruit juice. Only relevant if you’re on atorvastatin, simvastatin, or lovastatin. Large daily glasses raise levels; occasional small servings are clinically minor. Not an issue with rosuvastatin, pravastatin, fluvastatin, or pitavastatin.
• Red yeast rice. Don’t combine with your prescribed statin — the effect stacks.

Earning a lower dose

If you’re on a statin for primary prevention and you genuinely change your eating, movement, weight, alcohol intake, and smoking status, your absolute cardiovascular risk may drop enough that we can reduce the dose — sometimes come off it. This is a real goal worth aiming for.

Two caveats. First, we do this together — with home BP, a repeat lipid panel, and a recalculated absolute-risk score, not on your own. Second, if you’re on the statin for secondary prevention (post-heart attack, post-stroke, post-revascularisation) or familial hypercholesterolaemia, the evidence supports staying on the medicine regardless of what the number does. The lifestyle changes are still worth making — they’re independent cardiovascular protectors. They just don’t earn you the right to stop the statin in that group.

---

Track these between now and your next visit

• Any new muscle symptoms — aches, tenderness, weakness. Note when they started, where, how often, whether they’re worse with activity, and whether you started any new medicine (including over-the-counter or supplements) around the same time.
• Anything new you’ve bought over the counter (red yeast rice, fish oil, CoQ10, berberine, plant sterols) — bring the bottles.
• Significant grapefruit intake if you’re on atorvastatin, simvastatin, or lovastatin.
• Your home BP readings if you’re also on BP medicine.
• Any new antibiotic course during the period — particularly macrolides (clarithromycin, erythromycin).

Bring the list to your review appointment.

---

This is general information, not personal medical advice. Every patient is different. Decisions about your medicines — which one, what dose, when to stop, what to combine with — are made with the doctor who prescribed them. If anything on this page appears to contradict advice from your treating doctor, follow your doctor; they have context about your situation that this page cannot.

Reading this page does not establish a doctor-patient relationship with Dr Hoebing Lo. If you are not a current patient, please discuss your medicines with your own GP, specialist, or pharmacist.

About the integrative content. The lifestyle, dietary, and complementary recommendations on this page summarise current published research. Effect sizes are approximations from clinical studies — your individual response will vary, and real-world results are commonly smaller than trial results because day-to-day life differs from study conditions. Supplements and herbal products are not interchangeable with prescribed medication and can interact with it. Talk to your doctor and pharmacist before starting any new supplement, herbal product, or significant change in diet.

Currency. This page reflects clinical practice as of the last-reviewed date. Medicine evolves; specific details may date between reviews. Pricing shown is indicative; confirm with your pharmacist.

No commercial relationships. Dr Hoebing Lo has no financial or commercial relationship with the manufacturer of any medicine, brand, or supplement mentioned on this page.

Emergencies. If you have severe muscle pain plus dark or tea-coloured urine, sudden chest pain, sudden severe weakness, or fainting, call 000 or go to your nearest emergency department. Do not wait, and do not message us first.